Literature DB >> 27367741

Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015).

Tryfon Zarganes-Tzitzikas1, Markella Konstantinidou1, Yongzhi Gao1, Dobroslawa Krzemien2, Krzysztof Zak2, Grzegorz Dubin2, Tad A Holak2,3, Alexander Dömling1.   

Abstract

Entities:  

Keywords:  PD-1; PD-L1; Programmed death-1; T-cell exhaustion; immune checkpoint; immune-oncology

Mesh：

Substances：

Year:  2016        PMID： 27367741      PMCID： PMC5379636          DOI： 10.1080/13543776.2016.1206527

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN： 1354-3776            Impact factor:   6.674


× No keyword cloud information.
  11 in total

1.  PD-1 Blockers.

Authors:  Jedd D Wolchok
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

2.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

3.  Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy.

Authors:  Hao-Nan Chang; Bei-Yuan Liu; Yun-Kun Qi; Yang Zhou; Yan-Ping Chen; Kai-Mai Pan; Wen-Wen Li; Xiu-Man Zhou; Wei-Wei Ma; Cai-Yun Fu; Yuan-Ming Qi; Lei Liu; Yan-Feng Gao
Journal:  Angew Chem Int Ed Engl       Date:  2015-08-10       Impact factor: 15.336

4.  Salicylates are interference compounds in TR-FRET assays.

Authors:  Ronan P Hanley; Shanti Horvath; Jianghong An; Fraser Hof; Jeremy E Wulff
Journal:  Bioorg Med Chem Lett       Date:  2015-12-17       Impact factor: 2.823

Review 5.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

6.  Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.

Authors:  Alexander Dömling; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2014-01-28       Impact factor: 15.336

7.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

Authors:  Krzysztof M Zak; Radoslaw Kitel; Sara Przetocka; Przemyslaw Golik; Katarzyna Guzik; Bogdan Musielak; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Structure       Date:  2015-10-22       Impact factor: 5.006

8.  Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.

Authors:  Roy L Maute; Sydney R Gordon; Aaron T Mayer; Melissa N McCracken; Arutselvan Natarajan; Nan Guo Ring; Richard Kimura; Jonathan M Tsai; Aashish Manglik; Andrew C Kruse; Sanjiv S Gambhir; Irving L Weissman; Aaron M Ring
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-10       Impact factor: 11.205

Review 9.  Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.

Authors:  Silvia Carvalho; Francesca Levi-Schaffer; Michael Sela; Yosef Yarden
Journal:  Br J Pharmacol       Date:  2016-03-14       Impact factor: 8.739

10.  Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).

Authors:  Krzysztof M Zak; Przemyslaw Grudnik; Katarzyna Guzik; Bartosz J Zieba; Bogdan Musielak; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Oncotarget       Date:  2016-05-24
View more
  28 in total

1.  Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide.

Authors:  Ben Niu; Todd C Appleby; Ruth Wang; Mariya Morar; Johannes Voight; Armando G Villaseñor; Sheila Clancy; Sarah Wise; Jean-Philippe Belzile; Giuseppe Papalia; Melanie Wong; Katherine M Brendza; Latesh Lad; Michael L Gross
Journal:  Biochemistry       Date:  2019-12-31       Impact factor: 3.162

Review 2.  Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

Authors:  Markella Konstantinidou; Tryfon Zarganes-Tzitzikas; Katarzyna Magiera-Mularz; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2018-02-23       Impact factor: 15.336

3.  In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action.

Authors:  Derek J Blevins; Ronan Hanley; Trevor Bolduc; David A Powell; Michael Gignac; Kayleigh Walker; Mark D Carr; Fraser Hof; Jeremy E Wulff
Journal:  ACS Med Chem Lett       Date:  2019-07-02       Impact factor: 4.345

4.  Fragment-based screening of programmed death ligand 1 (PD-L1).

Authors:  Evan Perry; Jonathan J Mills; Bin Zhao; Feng Wang; Qi Sun; Plamen P Christov; James C Tarr; Tyson A Rietz; Edward T Olejniczak; Taekyu Lee; Stephen Fesik
Journal:  Bioorg Med Chem Lett       Date:  2019-01-24       Impact factor: 2.823

Review 5.  Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.

Authors:  Fabian Krutzek; Klaus Kopka; Sven Stadlbauer
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-14

Review 6.  Peptide/protein-based macrocycles: from biological synthesis to biomedical applications.

Authors:  Wen-Hao Wu; Jianwen Guo; Longshuai Zhang; Wen-Bin Zhang; Weiping Gao
Journal:  RSC Chem Biol       Date:  2022-06-09

7.  Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

Authors:  Katarzyna Magiera-Mularz; Lukasz Skalniak; Krzysztof M Zak; Bogdan Musielak; Ewa Rudzinska-Szostak; Łukasz Berlicki; Justyna Kocik; Przemyslaw Grudnik; Dominik Sala; Tryfon Zarganes-Tzitzikas; Shabnam Shaabani; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2017-09-26       Impact factor: 15.336

Review 8.  A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).

Authors:  Shabnam Shaabani; Harmen P S Huizinga; Roberto Butera; Ariana Kouchi; Katarzyna Guzik; Katarzyna Magiera-Mularz; Tad A Holak; Alexander Dömling
Journal:  Expert Opin Ther Pat       Date:  2018-09-10       Impact factor: 6.674

9.  Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists.

Authors:  Roberto Butera; Marta Ważyńska; Katarzyna Magiera-Mularz; Jacek Plewka; Bogdan Musielak; Ewa Surmiak; Dominik Sala; Radoslaw Kitel; Marco de Bruyn; Hans W Nijman; Philip H Elsinga; Tad A Holak; Alexander Dömling
Journal:  ACS Med Chem Lett       Date:  2021-04-28       Impact factor: 4.345

10.  Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.

Authors:  Wenjie Zhai; Xiuman Zhou; Mingxia Zhai; Wanqiong Li; Yunhui Ran; Yixuan Sun; Jiangfeng Du; Wenshan Zhao; Lingxiao Xing; Yuanming Qi; Yanfeng Gao
Journal:  Sci China Life Sci       Date:  2020-07-28       Impact factor: 6.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.